GlassScriptPhysician profile
Carlos A Medina
NPI 1972554954
$9,177.81
in general payments reported to CMS, 2019-2025
37 companies · $1,199 in 2025
The $1,199 reported for 2025 was more than what 89% of Pediatric Pulmonology providers received nationally (typical 2025 total: $140).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,197 · 2020: $944 · 2021: $1,439 · 2022: $1,751 · 2023: $1,203 · 2024: $1,444 · 2025: $1,199.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,847.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,847.08 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,313.67 | 2019-2025 | Tezspire, Fasenra |
| Grifols USA, LLC | $683.40 | 2020-2025 | Xembify, Gamunex-C |
| Genzyme Corporation | $620.56 | 2019-2025 | |
| Vertex Pharmaceuticals Incorporated | $609.17 | 2019-2025 | Trikafta |
| Glaxosmithkline, LLC. | $589.13 | 2019-2025 | Nucala |
| Takeda Pharmaceuticals U.S.A., INC. | $552.13 | 2020-2025 | Hyqvia, Cuvitru |
| Abbvie INC. | $489.03 | 2019-2022 | |
| Covis Pharma Gmbh | $424.73 | 2019-2023 | |
| Novartis Pharmaceuticals Corporation | $395.31 | 2019-2024 | |
| Regeneron Healthcare Solutions, INC. | $393.19 | 2020-2024 | Dupixent |
| Genentech USA, INC. | $326.50 | 2020-2025 | Xolair |
| Sobi, INC | $290.52 | 2019-2022 | |
| Amgen INC. | $287.97 | 2021-2025 | Tezspire |
| Philips North America LLC | $271.48 | 2019-2025 | (Ak6) Vest Therapy, Vest Therapy Und |
| Baxter Healthcare | $233.78 | 2022-2025 | Hillrom - Vest System Model 105 Home Care, Hillrom - Visivest Airway Clearance System |
Show all 37 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $182.61 | 2019-2022 | |
| Csl Behring | $151.43 | 2019-2025 | Hizentra, Privigen |
| Octapharma USA, INC. | $141.40 | 2023-2025 | Panzyga, Octagam Immune Globulin (Human) |
| Teva Pharmaceuticals USA, INC. | $125.92 | 2021-2023 | |
| Electromed, INC. | $122.01 | 2019-2022 | |
| Horizon Therapeutics Plc | $99.24 | 2022-2023 | Actimmune |
| Allergan, INC. | $95.10 | 2019 | |
| Ars Pharmaceuticals Operations, INC. | $95.03 | 2025 | Neffy |
| Chiesi USA, INC. | $93.96 | 2020-2022 | |
| Pharming Healthcare, INC. | $73.02 | 2024-2025 | Ruconest |
| Nestle Healthcare Nutrition INC. | $72.25 | 2021-2023 | |
| Mylan Specialty L.P. | $71.97 | 2019-2021 | |
| Gilead Sciences, INC. | $70.76 | 2020-2022 | |
| Aytu Biopharma, INC. | $55.36 | 2020-2021 | |
| Zambon USA LTD. | $54.36 | 2022 | |
| Shire North American Group INC | $50.37 | 2019 | |
| Advanced Respiratory, INC | $37.18 | 2019 | |
| Pfizer INC. | $26.27 | 2021 | |
| Abbott Laboratories | $22.89 | 2022 | |
| Alk-Abello, INC | $20.65 | 2022 | |
| Kaleo, INC. | $20.27 | 2023 | Auvi-Q |
| Vivus LLC | $15.19 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Carlos Medina listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.